louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03847259: Mechanical Posture Changes in Adolescent Female at Public Schools Compared to International Schools
Official title: Mechanical Posture Changes in Adolescent Female at Public Schools Compared to International Schools
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adolescent Behavior
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-02-20
Enrollment: 200
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adolescent female at schools.

Brief summary: The aim of this study is to determine different mechanical posture changes in adolescent females at public schools compared to international schools.

Detailed description: Two hundred adolescent female subjects at public schools and in this study. All subjects will be recruited from different schools. 1-Group A: it will be consists of 200 adolescent female from public schools, will be evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS)and Depression Anxiety Stress Scales-21(DASS-21).

2- Group B: it will be consists of 200 adolescent female from international schools, will be evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS) and Depression Anxiety Stress Scales-21(DASS-21).

Eligibility criteria: Inclusion Criteria:

1. Adolescent female at schools.
2. Their age will be ranged from 13 to 17 years.
3. BMI more than 20.
4. Initiated menstrual cycle.

Exclusion Criteria:

1. Asthma and chronic respiratory disease.
2. History of upper and lower limb injury.
3. Under weight subjects.
4. Females with congenital spinal deformities.
5. Diabetes, cardiopulmonary diseases and any physical impairment that prevent following the study program.

Primary outcomes:
measure: posture deviations
timeFrame: up to 6months
Secondary outcomes:
measure: weight
timeFrame: up to 6months
measure: height
timeFrame: up to 6months
measure: body mass index (BMI).
timeFrame: up to 6 months
measure: Back Pain and Body Posture Evaluation Instrument (BackPEI) questionnaire
timeFrame: up to 6months
measure: Visual analogue scale
timeFrame: up to 6months
measure: Depression Anxiety Stress Scales-21(DASS-21)
timeFrame: up to 6months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo university
Study officials:
affiliation: Cairo University
name: fahema me okeel, phD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02383459: Observatory of Food Preferences in Infants and Children
Official title: Longitudinal Study of Food Liking in Eatrly Childhood
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eating Behavior
Lead sponsor: Centre des Sciences du Goût et de l'Alimentation
Sponsor class: OTHER
Collaborators: name: National Research Agency, France
name: Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
name: Institut National de la Santé Et de la Recherche Médicale, France
name: University of Burgundy
First posted: 2015-03-09
Enrollment: 319
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: Food habits form early in infancy and are likely to track into childhood until the beginning of adulthood. Understanding the factors driving the acceptance of foods in the early years is therefore of particular importance, since these foods will form the basis of a child's future food repertoire. This is especially important for vegetables, which consumption is recommended at all stages of life but is below the recommended levels and which acceptance is difficult to promote during late childhood.

The objective of the present study was to unravel the respective contribution of maternal feeding practices, of children's rate of exposure to vegetables and of children's sensory reactivity factors over the course of the first two years, to explain the development of liking for vegetables at the age of 2 years. This analysis took advantage of data recorded in a prospective cohort of children recruited before birth and followed up longitudinally until the age of 2 years.

Detailed description: This study is a cohort study with the aim to evaluate prospectively food liking in children, at to relate this outcome to children's food experience, acceptance of taste and olfactory stimulation, and to parental feeding style.

Eligibility criteria: Inclusion Criteria:

* Pregnant mothers older than 18 years

Exclusion Criteria:

* Food allergies in the infant, as observed after the infant's birth

Primary outcomes:
measure: Food likes (Evaluation of food likes for a list of 257 foods)
timeFrame: 1-year prospective data collection
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04304859: Brief Assessment of Impaired Cognition
Official title: Brief Assessment of Impaired Cognition
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dementia
Keywords: validation
casefinding tool
Lead sponsor: Danish Dementia Research Centre
Sponsor class: NETWORK
First posted: 2020-03-11
Enrollment: 428
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cases: Patients referred from GP for diagnostic evaluation Controls: Participating patients' relatives and volunteers from ongoing research projects at the involved memory clinics.

Brief summary: The aim is to develop and validate a new brief and accurate case-finding instrument for dementia and cognitive impairment - BASIC

Detailed description: The case-finding instrument consists of four components: a. patient-directed questions, b. supermarket fluency, c. category-cued Memory Test, d. informant-directed questions.

The data collection was carried out at five outpatient memory clinics in Denmark

Eligibility criteria: Inclusion Criteria:

* fluent in Danish

Exclusion Criteria:

* impaired eyesight or hearing

Primary outcomes:
measure: Brief Assessment of Impaired Cognition (BASIC)
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: DDRC
Study officials:
affiliation: Danish Dementia Research Centre
name: Gunhild Waldemar
role: STUDY_DIRECTOR
References:
Clinical trial NCT03411759: Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
Official title: Exploratory Study of Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Analgesia
CYP2D6 Polymorphism
Opioid Use
Chronic Pain
Keywords: CYP2D6
Chronic pain
Cytochrome P450
Opioids
Lead sponsor: University of Bologna
Sponsor class: OTHER
First posted: 2018-01-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chronic pain patients who are treated in a pain therapy clinic

Brief summary: The use of titrated drugs is at the base of a successful antalgic treatment in order to provide both an adequate relief and a satisfactory tolerability profile. These molecules, though, have a varying degree of efficacy in different subjects due to medical and genetic reasons. The latter are mainly represented by cytochrome (CYP) P450, in particular CYP2D6's polymorphisms are responsible for the diversified metabolism of analgesics used in chronic pain treatments.

Four main types of enzymatic metabolism make up the population, each one defined by a different CYP2D6 allele: extensive metabolizers, ultra-rapid metabolizers, intermediate metabolizers and poor metabolizers.

Moreover, regarding polytherapies, the analgesics' metabolism could be influenced by coadministration of other drugs, thus determining an inhibition or induction of the metabolic enzymes - known as phenocopying - and potentially also a change in the metabolic phenotype itself. The final outcome is the inconstancy of effectiveness and of the risk of developing side effects.

The primary objective of this study is to define a genetic pattern for the gene CYP2D6 by assessing the incidence of poor or ultrarapid metabolizers in a population of chronic pain patients. This will also allow to observe phenocopying in the same population.

Hence 100 patients diagnosed with chronic pain will be enrolled. The genetic pattern of the gene CYP2D6 of such patients will be examined by taking mouth samples. At the same time parametric tests for paired data to survey the correlations between phenotypical patterns and pharmacological therapies will be conducted.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of chronic pain

Exclusion Criteria:

-

Primary outcomes:
measure: Analyzing the genetic pattern of CYP2D6's genes
timeFrame: 8-10 months
Secondary outcomes:
measure: Evaluating the incidence of metabolic phenotype's variation
timeFrame: 8-10 months
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Andrea Fanelli
Study officials:
References:
citation: Fanelli A, Palazzo C, Balzani E, Iuvaro A, Pelotti S, Melotti RM. An Explorative Study of CYP2D6's Polymorphism in a Sample of Chronic Pain Patients. Pain Med. 2020 May 1;21(5):1010-1017. doi: 10.1093/pm/pnz265.
Clinical trial NCT05170659: Expanded Access for Relatlimab
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2021-12-28
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: This is an expanded access designed to provide access to Relatlimab for eligible participants.



Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT00555659: Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody Fusions
Official title: Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Degeneration
Spondylosis
Spondylolithesis
Stenosis
Keywords: Degeneration
Spondylosis
Spondylolisthesis
Stenosis
Lead sponsor: Columbia Orthopaedic Group, LLP
Sponsor class: OTHER
Collaborators: name: DePuy Spine
First posted: 2007-11-09
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any person who comes into the clinic and gives consent to participate in this prospective study.

Brief summary: Introduction: Degenerative changes of the discs and facet joints in the lumbar spine can result in pain and disability from spondylosis, spondylolisthesis and stenosis. Patients who are suffering with back and/or leg pain are potential candidates for an ALIF procedure.

Purpose: To assess and compare clinical outcomes and fusion rates in patients undergoing an instrumented ALIF procedure. Comparisons in all variables will be made across diagnostic categories. Comparisons between type of interbody spacer, graft type, and type of instrumentation will also be made

Detailed description: To assess and compare clinical outcomes and fusion rates in patients undergoing an instrumented ALIF procedure. Comparisons in all variables will be made across diagnostic categories. Comparisons between type of interbody spacer, graft type, and type of instrumentation will also be made.

This study is part of a larger Continuous Quality Improvement initiative at the Columbia Orthopaedic Group. The purpose of this effort is to improve surgical and non-surgical outcomes by using rigorous statistical analysis of our outcomes to guide our treatment decisions. Through an iterative feedback process we hope to optimize patient outcomes.

Eligibility criteria: Inclusion Criteria:

* Standard of care

Exclusion Criteria:

* Standard of care

Primary outcomes:
measure: Intake data will include all fields traditionally associated with a detailed note. Subsequent visit instruments will include visual analog scale and oswestry disability index.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbia
country: United States
facility: Columbia Orthopaedic Group
state: Missouri
Study officials:
affiliation: Columbia Orthopaedic Group, LLP
name: John D Miles, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00566059: Computed Tomographic Angiography or Conventional Coronary Angiography in Clinical Decision Making
Official title: Comparison Between Invasive Coronary Angiography and Dual-Source Computed Tomography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Coronary Artery Stenosis
Keywords: therapeutic advice
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
First posted: 2007-12-03
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients over 50 years of age, scheduled for elective coronary angiography

Brief summary: Patients planned for elective conventional coronary angiography will undergo CT coronary angiography (Dual Source CT) in order to assess the correlation of stenosis detection and therapeutic advice between conventional and CT coronary angiography. We hypothesize that their is a good correlation between conventional and CT coronary angiography for stenosis detection and therapeutic advice.


Eligibility criteria: Inclusion Criteria:

* Over 50 years of age
* Scheduled for elective coronary angiography

Exclusion Criteria:

* Patients with known iodine allergy
* Severe renal insufficiency (creatinine levels \> 120 micromol/L)
* Hyperthyroidism
* Cardiac arrhythmias
* Unstable clinical condition
* Inability to follow breath-hold commands
* Previous PCI or CABG were excluded.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
Study officials:
affiliation: University Medical Center Groningen
name: Felix Zijlstra, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04178759: Impact of Chemotherapy and Regenerative Markers of Liver Regeneration After Liver Resection for Liver Metastases
Official title: Impact of Chemotherapy and Regenerative Markers on Liver Regeneration After Liver Resection for Liver Metastases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Liver Regeneration
Liver Metastases
Keywords: Liver metastases
Liver regeneration
Markers
Lead sponsor: Vilnius University
Sponsor class: OTHER
First posted: 2019-11-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Liver is special organ, which can regenerate. On that ability there are many treatment modalities, where liver resection is performed, especially in cancer patients with liver metastases. Liver regeneration provides an opportunity for these patients to undergo multiple treatment regimes and liver resections to achieve curability. There are many factors that impair liver regeneration. One of these factors is chemotherapy. Literature data on impact of chemotherapy to liver regeneration is ambiguous. Therefore we aim to research impact of chemotherapy to liver regeneration.

Detailed description: Liver is the largest parenchymal organ responsible for over 500 different functions in human body, which are detoxification of various toxins, drugs, synthesis of proteins and enzymes, coagulation factors. Liver is special organ, which can regenerate. If 75% of liver is removed it can regenerate to its normal size. Liver volume is very important to liver function, if there is volume insufficiency it could lead to liver failure in addition to other factors that impair liver regeneration. On that regenerative ability there are many treatment modalities, when liver resection is performed, especially in cancer patients with liver metastases. Modern treatment modalities are based on combination of different treatments, surgical and chemotherapeutic. On the other hand, side effects of chemotherapy should not be discarded, which can increase patient morbidity and mortality. Thus, liver regeneration provides an opportunity for these patients to undergo multiple treatment regimes and liver resections to achieve curability. Literature data on impact of chemotherapy to liver regeneration is ambiguous. Therefore we aim to research impact of chemotherapy to liver regeneration.

Eligibility criteria: Inclusion Criteria:

• Patients with liver lesions, who are eligible for liver resection

Exclusion Criteria:

* Pregnant women
* Liver resection is not performed

Primary outcomes:
measure: Volume of regenerated liver after liver resection
timeFrame: 30 days
Secondary outcomes:
measure: Evaluation of liver fibrosis
timeFrame: 30 days
measure: Evaluation of liver markers responsible for liver regeneration
timeFrame: 30 days
measure: Evaluation of short term surgical outcomes
timeFrame: 90 days
Other outcomes:
Locations:
city: Vilnius
country: Lithuania
facility: Vilnius University Hospital Santaros Clinics
Study officials:
References:
Clinical trial NCT02041559: The Effect of Different Doses of Remifentanil on Kidney Function During Robot Assisted Prostatectomy - A Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prostate Cancer
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2014-01-22
Enrollment: 1500
Sex: MALE
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: male patients undergoing robot assisted prostatectomy

Brief summary: Robot assisted prostatectomy reduces the patients' postoperative pain and leads to rapid rehabilitation. But pneumoperitoneum affects the kidney. The increase of stress hormone reduces the glomerular filtration and the vaso-contraction of renal vessels leads the renal ischemia. Remifentanil is analgesics coupled with μ opioid receptor. In high dose of remifentanil, it is associated with κ and δ receptors, which leads to renal protection effect in animal study. Also, remifentanil infusion during anesthesia showed a diuretic effect. The purpose of this study is to investigate the remifentanil effect on renal function during robot assisted prostatectomy.


Eligibility criteria: Inclusion Criteria:

* ages \> 19 years and \< 85 years
* the patients undergoing a general anesthesia for robot assisted prostatectomy

Exclusion Criteria:

* incomplete record
* history of opioid or steroid using
* solitary kidney
* history of kidney transplantation

Primary outcomes:
measure: acute kidney injury incidence based on Acute Kidney Injury Network criteria
timeFrame: 24 hours after end of surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University Health System
Study officials:
References:
Clinical trial NCT00998959: Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients
Official title: Feasibility and Efficacy of a Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Major Depressive Disorder
Keywords: Depression
Major Depression
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Dupont-Warren
First posted: 2009-10-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the usefulness of a stress reduction treatment in helping minority patients with major depression get better. Subjects will receive six weeks of either mindfulness-based stress reduction and problem solving therapy or psychoeducation.

Detailed description: The purpose of this study is to determine the usefulness of a stress reduction treatment compared to psychoeducation in helping minority patients with major depression get better.

The study will last 10 weeks. During the main portion of the study, subjects will receive either individual weekly sessions of stress-reduction therapy or psychoeducation for six weeks. The stress reduction therapy will consist of mindfulness-based stress reduction and problem solving therapy, which focuses on linking psychological problems with psychosocial issues and helping you use your skills and resources to improve your functioning. The psychoeducation will consist of six sessions of education on depression and the treatment and management of symptoms. Each session will last 50 minutes, and four of the visits will also include filling out questionnaires which will take approximately 15-30 minutes to complete. One month after the last session, subjects will come in for a follow-up visit with a study clinician to see how they are doing and to fill out questionnaires.

Eligibility criteria: Inclusion Criteria:

* Meet criteria for current major depressive disorder
* Men or women aged 18-75 who self-identify as a member of a racial or ethnic minority group
* Has a PCP, therapist, psychiatrist, etc aware of their depression. Or, subject agrees to seek outside mental health treatment/management

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: Feasibility (rate of enrollment, attrition)
timeFrame: 2 years
Secondary outcomes:
measure: Perceived stress
timeFrame: Week 10
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Trina E. Chang, MD
role: PRINCIPAL_INVESTIGATOR
References: